@spinogenix

Spinogenix Announces FDA-Authorized Expanded Access Programfor SPG302, the First Synaptic Regenerative Therapy to Treat ALS - Spinogenix

Spinogenix Announces Open Enrollment for Phase 2 US Trial Following FDA Clearance of IND Application for SPG302, the First Synaptic Regenerative Therapy for Schizophrenia

Spinogenix Completes Phase 2 Study of SPG601 for Treatment of Fragile X Syndrome, a Common Inherited Form of Autism, Showing Strong Efficacy Signal in Measures of Abnormal Brain Activity

Spinogenix's SPG601 Receives FDA Fast Track Designation for Fragile X Syndrome

FDA Grants Fast Track Designation to Spinogenix’s SPG601 for Treatment of Fragile X Syndrome, a Common Inherited Form of Autism - Spinogenix

Spinogenix Appoints American Football Hall of Famer and Health Advocate Steve Young to its Board of Directors - Spinogenix

Blog - Spinogenix

pharmashots.com

To Reverse Aging’s Clock, Adjust the Cell’s Machinery

Companies To Watch: Spinogenix

Spinogenix Announces Launch of Glaucoma Program and Addition of World-Renowned Expert Dr. Robert Weinreb to its Science Advisory Board - Spinogenix

Synapse-restoring pill set for human trials as novel schizophrenia treatment

First Synaptic Regenerative Therapy for Schizophrenia Under Investigation

Spinogenix Announces Launch of a Phase 2 Clinical Trial Evaluating SPG302 for the Treatment of Schizophrenia - Spinogenix

SPG601 for Restoring Synaptic Function in FXS

Channel 7 News Australia Feature

Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer’s Disease - Spinogenix

Blog - Spinogenix

Spinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 Fragile X Syndrome - Spinogenix

What are the Current Investment Trends in the Pharmaceutical Industry, and How are They Influencing the Sector’s Direction?

Synapse-regenerating drug could reverse decline in Alzheimer’s - Drug Discovery World (DDW)

Courage and Connections: Dan Doctoroff and Stella Sarraf Discuss ALS, Synapses, and Spinogenix’s Innovative Approach - Spinogenix

FDA grants orphan designation to Fragile X syndrome therapeutic

Spinogenix Announces U.S. FDA Approval of its Investigational New Drug Application for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndrome

MSN

The structure of an Amyloid Precursor Protein/talin complex indicates a mechanical basis of Alzheimer’s Disease

ClinicalTrials.gov

SPG302 trial set to begin in Australia | MND Australia

Using EEG and TMS to capture treatment-related Brain Signals in Spinogenix Drug Trials

Actor Aaron Lazar opens up about ALS diagnosis

Investigating Auditory Electrophysiological Measures of Participants with Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Event-Related Potential Studies

onlinelibrary.wiley.com

Dysfunction of central control of breathing in amyotrophic lateral sclerosis - PubMed

SPG302 tested in a TAR4/4 ALS model by Dr. Justin Ichida at USC

6th Annual ALS ONE Research Symposium: Day 2 Industry Speaker: Peter Vanderklish, PhD of Spinogenix.

SPG302 Reverses Synaptic and Cognitive Deficits Without Altering Amyloid or Tau Pathology in a Transgenic Model of Alzheimer’s Disease - Neurotherapeutics

An interaction between synapsin and C9orf72 regulates excitatory synapses and is impaired in ALS/FTD - Acta Neuropathologica

Integrative proteomics highlight presynaptic alterations and c-Jun misactivation as convergent pathomechanisms in ALS - Acta Neuropathologica

Spinogenix Awarded Department of Defense Grant

Spinogenix Website

Spinogenix Awarded $3 Million NIH Alzheimer's Grant